. . . "# Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12093318 # Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12269863 # Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance] Nippon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15056946 # Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12434581 # Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11152011"@en . "Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist."@en . . . . "approved"@en . "Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack."@en . . "N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine"@en . "Humans and other mammals"@en . "Rizatriptan"@en . . "* 140 L [male] * 110 L [female]"@en . "N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine"@en . . . . "Rizatriptanum"@en . "MK 462 free base"@en . . . . . . "Rizatriptan benzoate"@en . . . "14%"@en . . . . . . "Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism."@en . . "For treatment of acute migraine attacks with or without aura."@en . . . "2-3 hours"@en . . "Rizatriptan benzoat"@en . . "Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism."@en . "Montserrat Armengol Asparo, Pere Dalmases Barjoan, \"Process for preparing a rizatriptan.\" U.S. Patent US20050148778, issued July 07, 2005."@en . . . . . . . . " "@en . . . . . . . . . "Risatriptan"@en . "145202-66-0"@en . . . . .